Torsades de Pointes after Ondansetron Infusion in 2 Patients
Texas Heart Institute Journal · 2017-10 · 44 (5) · 366-369
DOI: 10.14503/thij-16-6040 ↗Kurz gefasst
Fallbericht in der Zeitschrift Texas Heart Institute Journal, 2017-10. Verfasst von Danny Y Lee und 2 weiteren Autor:innen. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Drugs that prolong the electrocardiographic QT interval increase the risk of ventricular arrhythmias, particularly torsades de pointes. Ondansetron, a 5-hydroxytryptamine type 3 receptor antagonist antiemetic, is one such drug. We present the cases of 2 patients who were given intravenous ondansetron and subsequently developed torsades de pointes. Both had normal QT intervals at baseline but were discovered to have risk factors that predisposed them to drug-induced QT prolongation and ventricular arrhythmias. We briefly review the mechanisms for torsades de pointes caused by QT-prolonging medications, describe characteristics that increase patients' susceptibility to drug-induced QT prolongation, and call attention to the risk of ventricular arrhythmias in patients who are given ondansetron.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
Lee, D. Y., Trinh, T., & Roy, S. K. (2017). Torsades de Pointes after Ondansetron Infusion in 2 Patients. Texas Heart Institute Journal, 44(5), 366-369. https://doi.org/10.14503/thij-16-6040
Vancouver
Lee DY, Trinh T, Roy SK. Torsades de Pointes after Ondansetron Infusion in 2 Patients. Texas Heart Institute Journal. 2017;44(5):366-369. doi:10.14503/thij-16-6040
BibTeX
@article{Lee2017,
author = {Lee, Danny Y and Trinh, Tri and Roy, Sion K},
title = {Torsades de Pointes after Ondansetron Infusion in 2 Patients},
journal = {Texas Heart Institute Journal},
year = {2017},
volume = {44},
number = {5},
pages = {366--369},
doi = {10.14503/thij-16-6040}
}
EUVIMED